- Home
- RDWR vs MLTX Comparison
RDWR vs MLTX Comparison
Compare RDWR & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDWR | MLTX |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDWR | MLTX |
|---|---|---|
| Price | $23.93 | $17.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $32.50 | $25.70 |
| AVG Volume (30 Days) | 223.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.29 | N/A |
| Revenue Next Year | $7.85 | N/A |
| P/E Ratio | $59.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.46 | $5.95 |
| 52 Week High | $30.57 | $62.75 |
Technical Indicators
Market Signals| Indicator | RDWR | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 57.93 |
| Support Level | $23.13 | $14.84 |
| Resistance Level | $25.07 | $19.15 |
| Average True Range (ATR) | 1.44 | 0.99 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 27.96 | 57.35 |
Price Performance
Historical ComparisonAbout RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.